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ABSTRACT
Background: It is recognized that, as a result of
variation in tissue anatomy, current
auto-injectors may have insufficient needle
length to achieve successful intramuscular
agent delivery in a number of patients. The
Zeneo auto-injector is a novel prefilled,
single-use, needle-free device currently in
development for intradermal, subcutaneous,
and intramuscular agent delivery across a
variety of clinical indications. We aimed to
evaluate delivery depth of the device calibrated
at pressure appropriate for intramuscular (IM)
administration.
Methods: This was a prospective single-center
study in healthy adult volunteers, in whom
each received a single injection of saline into
the anterolateral thigh. Using sequential MRI
scans, we measured skin-to-muscle distance
(STMD) agent delivery depth, and the success
of IM agent penetration. Device dynamic
pressure measurements were also recorded.
Results: Results are reported for 37 subjects
with evaluable MRI scans; 19 men, 18 women;
mean age 38 years (range 20–58); mean BMI
27.0 kg/m2 (range 21.2–30.8 kg/m2). Mean
STMD values were 18.6 mm (range
13.4–23.6 mm) in women and 10.0 mm (range
5.0–21.7 mm) in men, with gender differences
due primarily to greater subcutaneous thickness
in women. A trend for greater STMD in subjects
with BMI greater than 25 kg/m2 was seen. Mean
injectate penetration depths of 30.1 mm (range
20.2–45.6 mm) were observed with values
similar in male and female subjects. Successful
IM delivery was reported in 95% of subjects.
When failure occurred, this was not due to
inadequate injection depth. Device pressure
(Pmax) had the greatest influence on injectate
muscle penetration.
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INTRODUCTION
In potentially life-threatening allergic reactions
or anaphylaxis (that may arise in response to a
number of different triggers), prompt
administration of intramuscular adrenaline/
epinephrine is the recommended treatment
[1–3]. Where possible, intramuscular (IM)
injection in the lateral thigh is the
recommended route of administration, as this
results in more rapid absorption and time to
peak plasma concentration compared with IM
injections via other sites (e.g., deltoid) and with
subcutaneous injections [3, 4]. In clinical
practice, use of adrenaline auto-injectors is a
standard approach for IM administration. A
number of different devices are available, which
vary regarding a number of characteristics
including needle length and device pressures.
However, some concerns have been reported
regarding the efficacy of some injector devices
to successfully deliver adrenaline to the IM
tissues because of inadequate needle length
[4–9]. Furthermore, with conventional
auto-injectors, use when required may be
reduced as a result of patient fears of injection
site pain or a more generalized needle phobia,
and accidental injuries may also occur [10, 11].
As such, alternative devices to improve use,
including needle-free technologies, are welcome.
Zeneo (Crossject, Chenoˆve, France) is a novel
prefilled, single-use, needle-free auto-injection
device currently in development for a variety of
clinical indications. This cartridge-based device,
specifically designed for self-administration,
works via gas propulsion of the drug through
micronozzles (250–300 lm diameter) (Fig. 1).
Automated drug delivery is triggered by
pushing the device onto skin in a simple ‘‘place
and push’’ approach, with the device
mechanisms housed within a protective casing.
By altering the propulsion pressure parameters of
the device, which impacts upon the depth of
delivery of the chosen agent, the device can be
tailored to deliver fixed doses of agents in a range
of volumes via the intradermal, subcutaneous
(SC), and intramuscular (IM) routes. The primary
objective of this study was to evaluate the
functional performance of this device in the
setting of IM delivery to the lateral thigh.
Outcomes of interest included the
skin-to-muscle distance (STMD) in the study
population, agent delivery depth, and the
success of IM agent penetration. Additional
outcomes included the impact of
anthropometric characteristics on device
performance. Safety data (tolerance and pain
assessments) and patient experience data were
also collected, and these will be the subject of a
subsequent broader report.
METHODS
Study Design and Study Population
This was a single-center study in healthy
volunteers performed between June and
December 2015 at the Centre d’Investigation
Clinique INSERM 1432, CHU Dijon-Bourgogne,
France. The study (Crossject study identifier:
G-E-CJT-XC-150127) was performed in
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accordance with Good Clinical Practice (GCP)
guidelines. All procedures followed were also in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Declaration of Helsinki (1964), as
revised in 2013 [12]. The study protocol was
reviewed and approved by an independent
ethics committee (Comite´ de Protection des
Personnes, CPP) and the French National
Agency for Medicines and Health Products
Safety (ANSM). All subjects provided written
informed consent before study inclusion.
The study recruited male or female healthy
volunteers agedbetween18and60 years andbody
mass index (BMI) 20–30 kg/m2. Prior to inclusion,
participants were screened and excluded if clinical
examination and/or laboratory investigations
were abnormal. At this visit, a range of physical
measurements were recorded, including height,
weight, and anthropometric measures (waist, hip,
and thigh size).
Intervention and Assessments
Subjects returnedwithin30 daysof screeningvisit
for evaluation of device performance. All subjects
were under medical supervision during the
procedure and for 1 h after the injection. After
skin surface antisepsis (with 60% ethanol) all
subjects received an injection of 0.9% saline
(0.625 ml) into the thigh with the needle-free
injector device. Injections were performed by
either a trained nurse or by the investigator and
applied perpendicular to the skin. During the
injection,devicedynamicpressuremeasurements
were recorded via a transducer, mounted on the
device, from which pressure parameters were
obtained, including Pinit (pressure at 0.7 ms) and
Pmax (maximum pressure after 2 ms).
For each subject, sequential MRI scanning was
performed within 7 min of the injection on a
3.0-T Siemens Trio Tim system (Siemens Medical
Solutions, Erlangen, Germany) with high
resolution T2-weighted 3D DESS (double echo
steady-state) sequences used to acquire high
contrast images capable of distinguishing the
injectate (saline) from muscle and subcutaneous
tissue. Images were analyzed for assessment of
qualitative and quantitative parameters to
characterize different injection/device functions.
Qualitative assessments included the success of
IM delivery, as assessed by MRI documented
muscle penetration. Quantitative assessments
included dermal and subcutis thickness at
injection site, STMD, and maximum penetration
of injectate. Image analysis was performed using
ImageJ open source software (NIH, USA).
Fig. 1 Zeneo auto-injector
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Data Analysis
Quantitative categorical and continuous
variables were described by the number of
data, mean ± standard deviation (SD), and
range, as appropriate. Differences between
groups (men vs women) were calculated using
the two-tailed t test for normally distributed
data. Principal component analysis (PCA) was
performed to identify those factors impacting
upon depth of agent delivery.
RESULTS
Baseline Demographic and Clinical
Characteristics
A total of 44 subjects received an IM injection.
Of these, four subjects were excluded because of
incorrect device technique; in three other
subjects, technical difficulties in MRI scans
rendered these unsuitable for analysis. As such,
a total of 37 subjects with evaluable MRI scans
were included in this analysis. Subject
characteristics are shown in Table 1. The
analysis population included very similar
numbers of men and women, with a mean age
of 38 years (range 20–58 years). Mean baseline
body weight was 77 kg (range 56.5–101.9 kg),
with a mean BMI of 27.0 kg/m2 (range
21.2–30.8 kg/m2).
Skin Thickness
The thickness of different tissue components
(dermis and subcutaneous tissues) and the
overall STMD are shown in Table 2. The MRI
scans showed that the mean dermal thickness
for the study population was 1.8 ± 0.3 mm
(range 1.1–2.4 mm) with few differences in
values between men and women. However, for
subcutaneous thicknesses, while for the overall
population, the mean thickness was
12.4 ± 5.8 mm (range 3.0–21.9 mm), there
were significant differences observed when
comparing women and men, with values of
16.9 ± 3.3 mm (range (12.0–21.9 mm) and
8.1 ± 4.4 mm (range 3.0–19.4 mm) respectively
(mean difference -8.8; 95% confidence interval
-11.4 to -6.2, P\0.0001). Consequently
significant differences in the STMD were also
seen, with mean STMD values of 18.6 ± 3.3 mm
(range 13.4–23.6 mm) in women, and
10.0 ± 4.7 mm (range 5.0–21.7 mm) reported
in men (mean difference -8.6; 95% CI -11.3
to -5.9, P\0.0001). For both SC thickness and
STMD, values were higher in subjects with BMI
greater than 25, although these differences were
not significant.
Device Pressure and Injection
Performance
Across the overall study population, the mean
Pinit was 155 bar (range 140–174 bar) and mean
Pmax was 212 bar (range 187–232 bar). This was
within the expected device pressure
performance profile. MRI scans were also
analyzed to measure delivery and penetration
depth of the injectate within muscle (Fig. 2).
Out of 37 subjects, 35 had MRI scans that
demonstrated IM penetration, while two
subjects had no identifiable IM injectate
component; this represents a success rate of
94.6%. The MRI scans showed that the mean
depth of injectate penetration was
30.1 ± 5.8 mm (range 20.2–45.6 mm) for the
overall study population, with minor,
non-significant differences observed between
male (28.6 ± 6.1 mm, range 20.9–39.2 mm)
and female subjects (31.5 ± 5.9 mm, range
20.2–45.6 mm) (Table 2). BMI showed little
impact upon injection depth.
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To develop an explanatory model to explore
the impact of key variables on injection depth,
we used principal component analysis (PCA).
STMD, Pmax, BMI, and thigh circumference
were all identified as being correlated with
injection depth (data not shown) with
multivariate linear regression analysis
suggesting that Pmax had the greatest impact
on increasing injection depth.
DISCUSSION
In this study, using MRI scanning, we evaluated
skin and subcutaneous thickness and STMD at
the lateral thigh in healthy volunteers. All
measurements were recorded following saline
injection via the Zeneo needle-free
auto-injector, and as such were performed on
tissue subject to tissue compression as a result of
device pressure, which represents the clinical
conditions in practice. While a number of
studies have evaluated skin measurements in
different populations using imaging modalities,
most have done so using ultrasound
[6, 7, 9, 13–15] and less commonly CT [5, 16],
relatively few studies have used MRI to evaluate
STMDs in the thigh, and primarily in children
[16]. MRI was used as the imaging modality, as
that also allowed assessment of in vivo agent
penetration and IM delivery. We are not aware
Table 1 Baseline characteristics of the study participants
All participants (n5 37) Men (n5 19) Women (n5 18)
Age (years) 38.3 (20–58) 38.5 (28–58) 38.1 (20–57)
Height (cm) 169 (155–192) 176 (164–192) 168 (155–168)
Body mass (kg) 77.0 (56.5–101.9) 83.0 (66.2–101.9) 70.7 (56.5–81.3)
BMI (kg/m2) 27.0 (21.2–30.8) 26.9 (21.2–30.8) 27.0 (21.4–30.4)
Waist size (cm) 89.2 (68–110) 93.6 (72–110) 84.4 (68–95)
Hip size (cm) 100.7 (85–115) 100.1 (87–115) 101.3 (85–110)
Thigh size (cm) 56.7 (47–69) 56.3 (47–69) 57.1 (47–67)
Data shown are mean (range), except where indicated otherwise
BMI body mass index
Table 2 Dermis, subcutaneous tissue, skin-to-muscle distance measurements, and agent penetration depth
Measurement (mm) All participants (n5 37) Men (n5 19) Women (n5 18)
Skin measurements
Dermis 1.8 ± 0.3 (1.1–2.4) 1.9 ± 0.3 (1.3–2.3) 1.7 ± 0.3 (1.1–2.4)
SC 12.4 ± 5.8 (3.0–21.9) 8.1 ± 4.4 (3.0–19.4) 16.9 ± 3.2* (12.0–21.9)
STMD (mm) 14.2 ± 5.8 (5.0–23.6) 10.0 ± 4.7 (5.0–21.7) 18.6 ± 3.3* (13.4–23.6)
Maximum agent penetration 30.1 ± 5.8 (20.2–45.6) 28.6 ± 6.1 (20.9–39.2) 31.5 ± 5.9 (20.2–45.6)
Data shown are mean ± SD (range)
SC subcutaneous tissue, SD standard deviation, STMD skin-to-muscle distance
* P\0.0001 (Student t test)
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of studies that have directly compared the
sensitivity/accuracy of these different imaging
modalities on measuring STMD; a study which
investigated such comparisons would of course
be of some interest in this respect (although
quite possibly challenging to perform). We
found that while the mean STMD for the
overall population was 14.2 mm, substantial
variation exists, with the distance ranging
from 5.0–23.6 mm. Furthermore, STMD was
greater in women. These data are broadly
similar to those reported in previous studies
(using ultrasound or CT) [5–7, 9, 13, 15] and
support the view that STMD is greater in women
than in men as a result of a greater SC thickness.
Some studies have discussed thigh STMD in
the context of typical needle length and the risk
of failure to achieve IM delivery. Using
measurements obtained by a retrospective
analysis of CT scans, Song et al. reported mean
STMDs of 6.6 mm (range 2.1–34.7 mm) in men
and significantly greater STMDs of 14.8 mm
(range 2.4–37.1 mm; P[0.0005) in women [5].
In that study, they also evaluated the number of
patients with an STMD of greater than
14.3 mm, on the rationale that use of a
standard 14.3-mm needle (a frequently used
needle length in auto-injector devices) would
fail to deliver an IM dose in these patients. They
found that while only 2% of men had an STMD
greater than 14.3 mm, and were at risk of
failure, 42% of women had an STMD
exceeding 14.3 mm [5]. Subsequent studies
have followed this approach, with greater
needle length, and also reported similar
concerns. Bhalla et al. evaluated potential risk
of IM failure based upon STMD greater than
15.9 mm and reported that 31% were at risk of
failure, with women being at far greater risk [7].
More recently, another US study found that
28% of women had an STMD greater than
15.2 mm, while a UK study found that 68% of
patients were at risk of IM failure with a needle
length of 15.02 mm [6, 15].
These data provide the basis for arguing the
need for greater needle lengths in devices for IM
delivery. This is supported by our study, where
we also found relatively high numbers of
subjects with STMDs exceeding the needle
length of commonly available auto-injectors.
In 17 out of 37 subjects (46%), the STMD was
greater than 14.3 mm. While only two men
(11%) had STMD greater than 14.3 mm, 15
women (83%) had STMD greater than this
value; 43% of subjects had an STMD greater
than 15.2 mm, 11% of all men and 78% of all
women. It should be recognized that the effect
of tissue compression in response to forces
required to trigger auto-injectors and also
subsequent needle propulsion forces may each
contribute to agent delivery depth [17]. Data
from a porcine model suggests that such forces
make a significant contribution to delivery
beyond the 14.3-mm needle length [18].
Nevertheless, it remains that successful IM
Fig. 2 MRI scan demonstrating successful intramuscular
injectate delivery into vastus lateralis. STMD skin-to-mus-
cle distance
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delivery with many current injectors of this
needle length is uncertain. This is reflected in
recommendations from Europe where UK
guidance is that a 25-mm needle should be
used when administering adrenaline/
epinephrine in anaphylaxis [19]. Furthermore,
albeit in the context of vaccination, the Centers
for Disease Control and Prevention (CDC) in
the USA also recommend use of a 25-mm needle
to ensure IM delivery in the thigh [20].
We also evaluated administration and IM
delivery of a test agent (saline) and measured
depth of delivery and also delivery success
within the thigh muscle. While studies
examining this have been performed using
animal models [18], we are not aware of
similar studies in humans. We found that use
of the Zeneo device, calibrated at pressure
appropriate for IM administration, resulted in
mean injectate penetration depths of 30.1 mm
(range 20.2–45.6 mm) with no meaningful
differences between male and female subjects.
Additionally, successful IM delivery was
reported in 35/37 (95%) of subjects. In those
cases of unsuccessful IM delivery, in one subject
the injectate traveled the entire STMD and
spread on the fascial surface, while in the
other case, the injectate traversed the
subcutaneous tissue but was directed to a
tendon area. This 95% success rate compares
favorably with the failure rates extrapolated
from the modeling data as reported above
[5–7, 15]. Although exploratory, our analyses
suggested that device pressure (Pmax) had the
greatest influence on injectate penetration. This
may be anticipated as the device is designed so
as to be capable of delivering to specific tissues
for specific indications (i.e., IM or SC) on the
basis of pressure settings.
Our study has a number of limitations. Our
study population is small, and, because of
prespecified inclusion criteria, while over 70%
of subjects were overweight (BMI [25 kg/m2),
only one had a BMI slightly above 30 kg/m2. As
such, there is limited data from the present
study regarding device performance, STMD, and
IM delivery success in obese patients (BMI
[30 kg/m2). This is an important consideration,
as it is well recognized that STMD is greater in
obese subjects (especially women) [5–7]. The
mean injectate penetration depths of
30.1 ± 5.8 mm we report would be sufficient
for reaching muscle in the great majority of
obese patients reported in these studies.
Furthermore, an inherent advantage of the
Zeneo system is that device pressure can be
modified to deliver agents to different delivery
depths—to suit the clinical indication—and so
can be altered should greater delivery depths for
IM penetration in obese patients with greater
STMDs be necessary. Studies evaluating Zeneo
device performance in obese patients are
ongoing.
The study was performed in one center in
France, and the subjects recruited may not be
representative of those from other areas.
Injections were administered by healthcare
staff with experience in device use, rather than
subject self-administration, and while we do not
anticipate lower rates, data is required to show
whether the injection depths and IM delivery
success will be similar following
self-administration. In this study we did not
formally analyze the volume of saline delivered
within the muscle, and so the proportion of
injectate deposited in the more superficial
dermal and subcutaneous tissues is unclear.
This aspect of the device performance is the
subject of further investigation. Finally, in the
present study, device use and saline injection
were performed directly against naked skin.
However, in the clinical context of adrenaline
injection, successful delivery through clothing
(e.g., denim) is an essential consideration. The
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effect of clothing on Zeneo device
performance has been investigated in allied, as
of yet unpublished, studies; these suggest that
there is no significant impact of administration
through clothing on depth of agent penetration
and IM delivery (Crossject, data on file).
Strengths of this study include the use of
MRI to document STDM measurements in a
realistic clinical setting, i.e., following use of an
auto-injector, along with measurement of
injectate depths and documented IM
penetration. To our knowledge, this is the first
such study to do so.
CONCLUSIONS
Our study reported STMDs similar to those
reported in other studies and with similar
gender differences, being significantly greater
in women. Use of the Zeneo needle-free
auto-injector achieves penetration depths
substantially greater than the needle length of
many currently available devices, with
successful IM agent delivery in 95% of subjects.
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